50 patients (18 male) received vigabatrin monotherapy during this study, to assess the efficacy and tolerability of first-line vigabatrin treatment for partial epilepsy. After 1 year, 70% of patients were seizure-free, 17% of patients had a reduction in seizure frequency of at least 50%, and 10% of patients had a reduction in seizure frequency of less than 50%. Only 3% of patients obtained no benefit from the therapy. Drug efficacy did not relate to either baseline seizure frequency or seizure aetiology. Adverse events were usually mild and transitory, and the main adverse events were weight gain and drowsiness. Our results show that vigabatrin may be considered a first-choice drug in newly diagnosed patients with partial epilepsy, owing to its good efficacy and tolerabilty.
|Number of pages||2|
|Journal||Medical Science Research|
|Publication status||Published - 1998|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)